Endocrine Abstracts

DHEAS, an adrenal steroid which displays antiatherogenic and cardioprotective actions, has been pointed as a marker of insulin sensivity (IS). No studies have inquired the effects of liraglutide on DHEAS levels and its relatioship with IS in patients with type 2 diabetes.Methods: We have studied 12 diabetic male patients (aged 48.6±10.4 years), before and after 6 months of liraglutide therapy. Liraglutide was initiated at 0.6 mg/day for a week and 1...

Introduction: The aim of this study was to analyze the effects of Liraglutide in hepatic steatosis as well as clinical and biochemical data before and after 6 months.Methods: We have retrospectively analysed epidemiological, anthropometric and laboratory data of 83 type 2 diabetic patients treated with Liraglutide and followed at different endocrinology units across east Andalusia. We have evaluated nonalcoholic fatty liver disease using liver enzymes an...

Background: Acromegaly is usually caused by a benign pituitary tumour, with increased production of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Treatment options include surgery, followed by pharmacological treatment with dopamine agonists, somatostatin analogues, GH receptor antagonists or radiotherapy. Treatment optimization is important to decrease the burden of this often-chronic disease on the patient.Objectives: To evaluate the ef...